These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 35235456)

  • 1. A novel mouse strain optimized for chronic human antibody administration.
    Gupta A; Smith P; Bournazos S; Ravetch JV
    Proc Natl Acad Sci U S A; 2022 Mar; 119(10):e2123002119. PubMed ID: 35235456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-tumor activity of human IgG1 anti-gp75 TA99 mAb against B16F10 melanoma in human FcgammaRI transgenic mice.
    Boross P; Jansen JH; van Tetering G; Nederend M; Brandsma A; Meyer S; Torfs E; van den Ham HJ; Meulenbroek L; de Haij S; Leusen JH
    Immunol Lett; 2014 Aug; 160(2):151-7. PubMed ID: 24613852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional humanization of immunoglobulin heavy constant gamma 1 Fc domain human
    Low BE; Christianson GJ; Lowell E; Qin W; Wiles MV
    MAbs; 2020; 12(1):1829334. PubMed ID: 33025844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elucidating the interplay between IgG-Fc valency and FcγR activation for the design of immune complex inhibitors.
    Ortiz DF; Lansing JC; Rutitzky L; Kurtagic E; Prod'homme T; Choudhury A; Washburn N; Bhatnagar N; Beneduce C; Holte K; Prenovitz R; Child M; Killough J; Tyler S; Brown J; Nguyen S; Schwab I; Hains M; Meccariello R; Markowitz L; Wang J; Zouaoui R; Simpson A; Schultes B; Capila I; Ling L; Nimmerjahn F; Manning AM; Bosques CJ
    Sci Transl Med; 2016 Nov; 8(365):365ra158. PubMed ID: 27856797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease.
    Petkova SB; Akilesh S; Sproule TJ; Christianson GJ; Al Khabbaz H; Brown AC; Presta LG; Meng YG; Roopenian DC
    Int Immunol; 2006 Dec; 18(12):1759-69. PubMed ID: 17077181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoclonal IgG can ameliorate immune thrombocytopenia in a murine model of ITP: an alternative to IVIG.
    Song S; Crow AR; Freedman J; Lazarus AH
    Blood; 2003 May; 101(9):3708-13. PubMed ID: 12506021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human IgG3 with extended half-life does not improve Fc-gamma receptor-mediated cancer antibody therapies in mice.
    Braster R; Grewal S; Visser R; Einarsdottir HK; van Egmond M; Vidarsson G; Bögels M
    PLoS One; 2017; 12(5):e0177736. PubMed ID: 28542406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. humanized mice to study FcγR function.
    Bournazos S; DiLillo DJ; Ravetch JV
    Curr Top Microbiol Immunol; 2014; 382():237-48. PubMed ID: 25116103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration.
    Smith B; Kiessling A; Lledo-Garcia R; Dixon KL; Christodoulou L; Catley MC; Atherfold P; D'Hooghe LE; Finney H; Greenslade K; Hailu H; Kevorkian L; Lightwood D; Meier C; Munro R; Qureshi O; Sarkar K; Shaw SP; Tewari R; Turner A; Tyson K; West S; Shaw S; Brennan FR
    MAbs; 2018 Oct; 10(7):1111-1130. PubMed ID: 30130439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monovalent Fc receptor blockade by an anti-Fcγ receptor/albumin fusion protein ameliorates murine ITP with abrogated toxicity.
    Yu X; Menard M; Prechl J; Bhakta V; Sheffield WP; Lazarus AH
    Blood; 2016 Jan; 127(1):132-8. PubMed ID: 26500340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease?
    Siragam V; Brinc D; Crow AR; Song S; Freedman J; Lazarus AH
    J Clin Invest; 2005 Jan; 115(1):155-60. PubMed ID: 15630455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The immunogenicity of antibody aggregates in a novel transgenic mouse model.
    Bessa J; Boeckle S; Beck H; Buckel T; Schlicht S; Ebeling M; Kiialainen A; Koulov A; Boll B; Weiser T; Singer T; Rolink AG; Iglesias A
    Pharm Res; 2015 Jul; 32(7):2344-59. PubMed ID: 25630815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mouse model recapitulating human Fcγ receptor structural and functional diversity.
    Smith P; DiLillo DJ; Bournazos S; Li F; Ravetch JV
    Proc Natl Acad Sci U S A; 2012 Apr; 109(16):6181-6. PubMed ID: 22474370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-inflammatory activity of CD44 antibodies in murine immune thrombocytopenia is mediated by Fcγ receptor inhibition.
    Norris PAA; Kaur G; Khan R; Zhu G; Ni H; Lazarus AH
    Blood; 2021 Apr; 137(15):2114-2124. PubMed ID: 33662988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity of different stressed IgG monoclonal antibody formulations in immune tolerant transgenic mice.
    Filipe V; Jiskoot W; Basmeleh AH; Halim A; Schellekens H; Brinks V
    MAbs; 2012; 4(6):740-52. PubMed ID: 22951518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-drug Antibodies Against a Novel Humanized Anti-CD20 Antibody Impair Its Therapeutic Effect on Primary Biliary Cholangitis in Human CD20- and FcγR-Expressing Mice.
    Moritoki Y; Tsuneyama K; Nakamura Y; Kikuchi K; Shiota A; Ohsugi Y; Lian ZX; Zhang W; Yang GX; Ueki S; Takeda M; Omokawa A; Saga T; Saga A; Watanabe D; Miura M; Ueno Y; Leung PSC; Tanaka A; Gershwin ME; Hirokawa M
    Front Immunol; 2018; 9():2534. PubMed ID: 30450101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonclinical evaluation of GMA161--an antihuman CD16 (FcγRIII) monoclonal antibody for treatment of autoimmune disorders in CD16 transgenic mice.
    Flaherty MM; MacLachlan TK; Troutt M; Magee T; Tuaillon N; Johnson S; Stein KE; Bonvini E; Garman R; Andrews L
    Toxicol Sci; 2012 Jan; 125(1):299-309. PubMed ID: 22025730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Production of antigen-specific human antibodies from mice engineered with human heavy and light chain YACs.
    Jakobovits A; Green LL; Hardy MC; Maynard-Currie CE; Tsuda H; Louie DM; Mendez MJ; Abderrahim H; Noguchi M; Smith DH; Zeng Y; David NE; Sasai H; Garza D; Brenner DG; Hales JF; McGuinness RP; Capon DJ; Klapholz S
    Ann N Y Acad Sci; 1995 Sep; 764():525-35. PubMed ID: 7486581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IgG glycan hydrolysis by a bacterial enzyme as a therapy against autoimmune conditions.
    Collin M; Shannon O; Björck L
    Proc Natl Acad Sci U S A; 2008 Mar; 105(11):4265-70. PubMed ID: 18332429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humanized FcRn mouse models for evaluating pharmacokinetics of human IgG antibodies.
    Proetzel G; Roopenian DC
    Methods; 2014 Jan; 65(1):148-53. PubMed ID: 23867339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.